Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Partow Kebriaei, MD, Matthias Stelljes, MD, Daniel J. DeAngelo, MD, Nicola Goekbuget, MD, Hagop M. Kantarjian, MD, Anjali S. Advani, MD, Akil Merchant, MD, Wendy Stock, MD, Tao Wang, PhD, Hui Zhang, Fausto Loberiza, Erik Vandendries, MD PhD, David Marks

Blood (2017) 130 (Supplement 1): 886.

https://doi.org/10.1182/blood.V130.Suppl_1.886.886

Published: 2017

Journal Articles

Long Term Outcomes for Patient with Diffuse Large B-Cell (DLBCL) or Hodgkin’s Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) Who Are Disease Free at Five Years Post Transplant.

Julie M. Vose, MD, Fausto Loberiza, Philip Bierman, Robert Bociek, James Armitage

Blood (2008) 112 (11): 2146.

https://doi.org/10.1182/blood.V112.11.2146.2146

Published: 2008

Journal Articles

Relapse from Complete Remission More Than 5 Years after Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Relapse Histology Most Commonly DLBCL with a Germinal Center B-Cell (GCB) Phenotype.

Julie M. Vose, MD, John C. Chan, MD, Philip J. Bierman, MD, Alejandro Arevalo, MD, Fausto Loberiza, MD, Kai Fu, MD, Dennis Weisenburger, MD, Robert G. Bociek, MD, Martin Bast, BS, James O. Armitage, MD

Blood (2007) 110 (11): 3430.

https://doi.org/10.1182/blood.V110.11.3430.3430

Published: 2007

Journal Articles

Outcome of Limited-Stage Peripheral T-Cell Lymphoma: Results from the Nebraska Lymphoma Study Group.

Philip Bierman, MD, Julie M. Vose, MD, R. Gregory Bociek, MD, Fausto Loberiza, MD, Martin Bast, BS, Dennis D. Weisenburger, MD, James Olen Armitage, MD

Blood (2007) 110 (11): 3451.

https://doi.org/10.1182/blood.V110.11.3451.3451

Published: 2007

Journal Articles

Outcomes of Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

John D. Dickinson, MD, PhD, Fausto Loberiza, MD, Victoria Whalen, Philip J. Bierman, MD, Julie M. Vose, MD, Marcel P. Devetten, MD, Lori J. Maness, MD, James O. Armitage, MD, Greg Bociek, MD

Blood (2007) 110 (11): 3045.

https://doi.org/10.1182/blood.V110.11.3045.3045

Published: 2007

Journal Articles

The Stanford V Regimen Is an Effective Treatment for Good Prognosis Patients with Hodgkin’s Disease.

Jamil Y. Abuzetun, Fausto Loberiza, Martin Bast, Julie M. Vose, Philip J. Bierman, R. Gregory Bociek, James O. Armitage

Blood (2007) 110 (11): 2323.

https://doi.org/10.1182/blood.V110.11.2323.2323

Published: 2007

Journal Articles

High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Lymphocyte Predominant Hodgkin’s Disease.

Philip Bierman, MD, Hina Naushad, MD, Fausto Loberiza, MD, R. Gregory Bociek, MD, Julie M. Vose, MD, James Olen Armitage, MD, Patricia Aoun, MD

Blood (2006) 108 (11): 3061.

https://doi.org/10.1182/blood.V108.11.3061.3061

Published: 2006

Journal Articles

Significance of c-myc Rearrangements in Diffuse Large B-Cell Lymphoma.

Philip Bierman, MD, Fausto Loberiza, MD, Bhavana Dave, PhD, Warren Sanger, PhD, R. Gregory Bociek, MD, Martin Bast, BS, Julie M. Vose, MD, James Olen Armitage, MD, Dennis Weisenburger, MD

Blood (2006) 108 (11): 2030.

https://doi.org/10.1182/blood.V108.11.2030.2030

Published: 2006

Journal Articles

Outcomes Following Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with or without Advanced Care Planning.

Apar Kishor Ganti, MD, Stephanie J. Lee, MD, MPH, James O. Armitage, MD, Philip J. Bierman, MD, Gregory Bociek, MD, Marcel P. Devetten, MD, Lori J. Maness, MD, Elizabeth C. Reed, MD, Julie M. Vose, MD, Fausto Loberiza, MD, MS

Blood (2005) 106 (11): 2025.

https://doi.org/10.1182/blood.V106.11.2025.2025

Published: 2005

Journal Articles

Low Dose Alemtuzumab (Campath 1H) Prior to Allogeneic Stem Cell Transplantation Is Associated with Low Incidence of Acute and Chronic GVHD but Protracted Immune Recovery.

Marcel P. Devetten, MD, Fausto Loberiza, MD, Robin Weisenborn, MT CCRC, Pam Bunner, MT CCRC, Jamie Brewer, Solveig Ericson, MD

Blood (2005) 106 (11): 5376.

https://doi.org/10.1182/blood.V106.11.5376.5376

Published: 2005

Journal Articles

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study

Jean-Yves Cahn, John P. Klein, Stephanie J. Lee, Noël Milpied, Didier Blaise, Joseph H. Antin, Véronique Leblond, Norbert Ifrah, Jean-Pierre Jouet, Fausto Loberiza, Olle Ringden, A. John Barrett, Mary M. Horowitz, Gérard Socié

Blood (2005) 106 (4): 1495–1500.

https://doi.org/10.1182/blood-2004-11-4557

Published: 2005

Journal Articles

Impact of Prior Pregnancy on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.

Alison Wakoff Loren, MD, MSCE, Greta R. Bunin, PhD, Christian Boudreau, PhD, Richard E. Champlin, MD, Avital Cnaan, PhD, Mary Horowitz, MD, MS, Fausto Loberiza, MD, MS, David L. Porter, MD

Blood (2004) 104 (11): 1638.

https://doi.org/10.1182/blood.V104.11.1638.1638

Published: 2004

Journal Articles

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Yogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, Jamie Robyn, Fausto Loberiza, Jaroslaw P. Maciejewski, Toni Simonis, Jeffrey Molldrem, Neal S. Young, A. John Barrett

Blood (2002) 100 (5): 1570–1574.

https://doi.org/10.1182/blood.V100.5.1570.h81702001570_1570_1574

Published: 2002

NARROW

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Long Term Outcomes for Patient with Diffuse Large B-Cell (DLBCL) or Hodgkin’s Lymphoma (HL) following Autologous Stem Cell Transplant (ASCT) Who Are Disease Free at Five Years Post Transplant.

Relapse from Complete Remission More Than 5 Years after Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Relapse Histology Most Commonly DLBCL with a Germinal Center B-Cell (GCB) Phenotype.

Outcome of Limited-Stage Peripheral T-Cell Lymphoma: Results from the Nebraska Lymphoma Study Group.

Outcomes of Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

The Stanford V Regimen Is an Effective Treatment for Good Prognosis Patients with Hodgkin’s Disease.

High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Lymphocyte Predominant Hodgkin’s Disease.

Significance of c-myc Rearrangements in Diffuse Large B-Cell Lymphoma.

Outcomes Following Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with or without Advanced Care Planning.

Low Dose Alemtuzumab (Campath 1H) Prior to Allogeneic Stem Cell Transplantation Is Associated with Low Incidence of Acute and Chronic GVHD but Protracted Immune Recovery.

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study

Impact of Prior Pregnancy on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only